Table 1.

Demographic and clinical characteristics at baseline, medication use, and biochemical assessment during treatment in patients with TRS by treatment group.

Variable		ARI (N = 100)	vB6 (N = 100)	P
Age, years		33.65 ± 3.03	29.99 ± 4.92	<0.001
Education	≤ 12 years	84 (84.0)	66 (66.0)	0.003
	>12 years	16 (16.0)	34 (34.0)
Disease duration before admission, weeks		6.09 ± 1.54	6.06 ± 1.41	0.40
Psychiatric family history	No	74 (74.0)	79 (79.0)	0.89
	Yes	26 (26.0)	21 (21.0)
Total drug dose in 16 weeks, mg		71,260.00 ± 9,424.43	70,262.00 ± 10,359.23	0.48
PANSS at baseline		91.63 ± 6.98	89.11 ± 3.56	0.002
Overall MCCB at baseline		29.82 ± 8.84	29.69 ± 9.17	0.92
Baseline data test data
Dose, mg/d		10	600	>0.99
Blood glucose, mmol/L		5.05 ± 0.59	5.02 ± 0.43	0.71
Triglycerides, mmol/L		1.37 ± 0.29	1.57 ± 0.07	<0.001
Cholesterol, mmol/L		4.79 ± 0.85	5.00 ± 0.16	0.02
Alanine aminotransferase, U/L		47.80 ± 12.72	47.95 ± 12.66	0.93
Aspartate aminotransferase, U/L		46.60 ± 11.97	46.04 ± 11.98	0.74
Gamma-glutamyl transferase, U/L		58.20 ± 11.33	58.88 ± 11.91	0.68
Creatinine, U/L		75.06 ± 16.06	74.09 ± 16.71	0.68
Blood urea nitrogen, U/L		3.63 ± 0.53	3.60 ± 0.52	0.77
Prolactin, μg/L		89.07 ± 3.59	95.52 ± 6.30	<0.001